Clinical Trial to Evaluate the Ingested, Space Occupying Hydrogel Capsules for Simple Obesity Treatment

NCT ID: NCT06530017

Last Updated: 2024-07-31

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 440 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-31
• Study Completion Date: 2026-06-30

Brief Summary

To evaluate the effectiveness and safety of Ingested, Space Occupying hydrogel capsules for simple obesity treatment

Detailed Description

Ingested, Space Occupying hydrogel capsules is indicated to aid in simple obesity treatment with a Body Mass Index (BMI) of 28-40 kg/m2，using under the guidance of a physician.This clinical trial seek to evaluate the efficacy and safety of Ingested, Space Occupying hydrogel capsules for simple obesity treatment.

Conditions

Simple Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Subjects in the Study group will be treated with Ingested, Space Occupying hydrogel capsules, which

During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water.

Group Type: EXPERIMENTAL

Ingested, Space Occupying hydrogel capsules

Intervention Type: DEVICE

During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water

Subjects in the Placebo group will be treated with placebo of the control medical device.

During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water.

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DEVICE

During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water

Interventions

Ingested, Space Occupying hydrogel capsules

During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water

Intervention Type: DEVICE

placebo

During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• The subjects have a BMI≥28kg/m²and BMI≤40kg/m²

Exclusion Criteria

• Individuals with secondary obesity, such as hypothyroidism, Cushing's syndrome, etc.
• Those who have undergo surgical method within the past 3 months prior to screening, or plan to lose weight by surgical method during the clinical trial.
• Weight loss exceeding >5% (self-report) within the past 3 months prior to screening.
• Individuals with uncontrolled diabetes mellitus (fasting blood glucose≥7.0mmol/L or glucose loading after 2 hours blood glucose≥11.1mmol/L or glycosylated hemoglobin≥7.0%) .
• Within 1 month before screening or planning to use drugs or health products that may cause significant weight gain or loss during the clinical trials, including biguanides,α-glycosidase inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, leptinoid drugs, sympathomimetic drugs, esterase inhibitors, lipolytic injections, sulfonamides, systemic glucocorticoids (more than 1 week), estrogen, thyroid hormones or preparations, antipsychotic or antidepressant drugs, Chinese patent medicines and Chinese herbal medicines, etc.
• Patients with central nervous system diseases (including but not limited to any type of seizures or strokes) and other related neurological diseases or mental illnesses.
• Those who have suffered or are suffering from swallowing disorders, gastroesophageal reflux disease, gastric or duodenal ulcers, gastroparesis, esophageal and gastric varices, intestinal obstruction or suspected small bowel adhesions, pyloric obstruction, Crohn's disease, ulcerative colitis and other diseases, acute/chronic pancreatitis, as well as a history of gastrointestinal surgery (except those related to appendectomy and intestinal polypectomy), abdominal radiation therapy, and gastrointestinal bleeding.
• Those who have AIDS or a history of cancer within the past 5 years.
• Patients with poorly controlled hypertension, i.e., systolic blood pressure (SBP) > 165mmHg and/or diastolic blood pressure (DBP) >95mmHg.
• Patients with renal insufficiency, i.e., estimated glomerular filtration rate (eGFR<30 ml/min/1.73m2)* calculated by the CKD-EPI creatinine equation as defined by the KDIGO 2012 classification.
• Patients with impaired liver function, that is, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal, or total bilirubin (TBIL) > 3 times the upper limit of normal.
• Those who stop smoking within the past 6 months before the screening period or consider stop smoking during the trial.
• Those who have planned surgery in the past 6 months.
• Pregnant or breastfeeding, planning to become pregnant during the trial (or males unwilling to use an adequate method of contraception), or having a positive pregnancy test result during the screening period.
• Individuals with a history of allergies to cellulose, titanium dioxide, citrate acid and succinic acid.
• Those with severe cardiovascular and cerebrovascular diseases or systemic failure that affects treatment.
• The investigator judges that the subject has other systemic diseases that are not suitable for participating in this trial, and the abnormal laboratory test results are determined by the investigator whether they can be enrolled.
• Participated in clinical trials of other drugs or medical devices within 30 days prior to the screening period.
• Other circumstances that the investigator deems inappropriate to participate in this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IMEIK Technology Development Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peng Li, M.D.

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Locations

Beijing Friendship Hospital,Capital Medical University

Beijing, Beijing Municipality, China

Peking University Shougang Hospital

Beijing, Beijing Municipality, China

Beijing Shijitan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

The First Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

The Third XiangYa Hospital of Central South University

Changsha, Hunan, China

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Shengjing Hospital Of China Medical University

Shenyang, Liaoning, China

The First Affiliated Hospital of Henan University of Science & Technology

Luoyang, Luoyang, China

QILU Hospital Of Shandong University

Jinan, Shandong, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Countries

China

Central Contacts

Wei Li

Role: CONTACT

liwei@imeik.com

13520464757

Other Identifiers

IMK-2023-NK001

Identifier Type: -

Identifier Source: org_study_id